Mesoblast acquires CAR platform to boost precision in cell therapies
Synopsis
Mesoblast has secured a CAR platform technology license from Mayo Clinic to enhance its cell therapy programs targeting inflammatory diseases. The Melbourne-headquartered company reported $51.3 million in first-half fiscal 2026 revenue while continuing clinical development. The deal reflects broader global momentum in cell therapy, with increasing use of CAR-based approaches beyond oncology.
Mesoblast has licensed CAR technology from Mayo Clinic to strengthen its cell therapy pipeline for inflammatory diseases. The company reported $51.3 million in first-half fiscal 2026 revenue.
Key Highlights
- Mesoblast CAR technology licensed from Mayo Clinic to enhance targeting of inflammatory disease treatments
- Platform extends CAR applications beyond oncology into immune and inflammatory conditions
- Company reported $51.3 million H1 FY2026 revenue with ongoing clinical development spending
- Global cell therapy market growing at double-digit rate, led by US and expanding in Asia-Pacific
Mesoblast Limited, headquartered in Melbourne and listed on the ASX and Nasdaq, has licensed chimeric antigen receptor (CAR) platform technology from Mayo Clinic, as it expands development of targeted cell therapies for inflammatory diseases.
The agreement gives Mesoblast access to CAR engineering methods applicable to its mesenchymal lineage cell therapies.
These therapies are designed to regulate immune responses, and the addition of CAR technology enables cells to better identify and act on specific disease sites.
Expanding beyond oncology use
CAR-based therapies are widely used in cancer care, particularly CAR-T treatments approved by US regulators over the past decade. Their use is now expanding into non-cancer conditions, including chronic inflammatory diseases such as Crohn’s disease and lupus nephritis.
The Mesoblast CAR technology integration reflects this broader shift. Companies and research centers are increasingly exploring how engineered cells can be directed toward inflamed tissues, rather than cancer cells alone.
Financials and pipeline development
Mesoblast reported revenue of approximately $51.3 million for the first half of fiscal 2026, supported by sales of its therapy Ryoncil. The company recorded a net loss of $40.2 million during the same period, consistent with continued spending on clinical-stage programs.
For the year ended June 2025, Mesoblast reported a net loss of about $102.1 million and cash reserves of $161.6 million.
The newly licensed CAR platform is expected to be integrated into existing and future development programs.
Sector momentum and global positioning
The global cell therapy market continues to expand, driven by regulatory approvals and clinical adoption. According to a 2025 report by Grand View Research, the sector is projected to grow at a double-digit annual rate through the decade.
The United States remains the largest market due to established approval pathways and treatment infrastructure, while Europe and Asia-Pacific countries, including Japan and South Korea, are increasing clinical activity through supportive regulatory frameworks.
The Mesoblast CAR technology deal aligns with this trend, as companies move toward more targeted and disease-specific cell therapies.
FAQs
Q1. What does the Mesoblast CAR technology deal involve?
Mesoblast licensed CAR platform technology from Mayo Clinic to improve targeting in its cell therapies.
Q2. Why is CAR technology important beyond cancer treatment?
It enables engineered cells to target inflammation, expanding use into immune-related diseases.
Q3. What are Mesoblast’s latest financial figures?
The company reported $51.3 million revenue in H1 FY2026 with continued net losses due to R&D spending.
Follow Inspirepreneur Magazine for daily global business news.
Pooja Malik is a business journalist with over six years of experience covering startups, entrepreneurship, and emerging trends. She has previously worked with leading media platforms such as YourStory Media and BW BusinessWorld, where she reported on business, policy, and market developments. Currently, she serves as Editor at The Inspirepreneur Magazine, where she writes and edits stories across business, lifestyle, and travel, with a focus on clarity, accuracy, and reader relevance.
You Might Also Like
Jeff Bezos-Backed AI Startup Hits $41B Valuation After $12 Billion Funding Round
Paul Ramsay: The Man Who Changed Healthcare in Australia with Ramsay Health Care
